Abstract: The present invention is directed to a stabilized bioactive hydrogel matrix coating for substrates, such as medical devices. The invention provides a coated substrate comprising a substrate having a surface, and a bioactive hydrogel matrix layer overlying the surface of the medical device, the hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component, the first and second high molecular weight components each being selected from the group consisting of polyglycans and polypeptides, wherein at least one of the first and second high molecular weight components is immobilized (e.g., by covalent cross-linking) to the surface of the substrate.
Type:
Grant
Filed:
November 9, 2007
Date of Patent:
December 17, 2013
Assignee:
Pioneer Surgical Technology, Inc.
Inventors:
Francis V. Lamberti, Richard Chris Klann, Ronald Stewart Hill
Abstract: Present invention relates to aqueous conditioning composition for keratin fibers especially for hair, which provides hair long lasting, several hair washes, conditioning effect. Accordingly, present invention is a conditioning composition for hair which comprises at least one polydimethylsiloxane with a viscosity of maximum 350 mm2/s at a concentration of 12.5% by weight or higher and polyquaternium 37 at a concentration of 0.2 to 5% by weight, calculated to total composition.
Abstract: Compositions and methods are disclosed for imparting a long-wearing color to keratin fibers, including hair. More specifically, the invention relates to cosmetic compositions and methods for improving retention of particulate materials, such as pigments, on hair to artificially color the hair and/or to impart other aesthetic benefits to the hair. The compositions comprise at least one aminosilicone polymer having at least one diamino functional group, and a functional group equivalent weight (FGEW) from about 1,000 to about 2,000 g/mol and a non-spherical particulate material, preferably a pigment or a lake.
Type:
Grant
Filed:
December 7, 2011
Date of Patent:
December 3, 2013
Assignee:
Avon Products, Inc.
Inventors:
Allwyn Colaco, Xiaolan Wei, Bing C. Mei
Abstract: Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones is from 10 to 16 carbon atoms and method for achieving such control or repellency.
Abstract: Therapeutic formulations adapted for positive-pressure application for controlling biological fluid at a desired site in a subject, absorbent articles comprising therapeutic formulations, and anti-infective devices coated with therapeutic formulations, said formulations comprising about 25% to about 99% by weight liquid-crystal forming compound and 0% to about 75% by weight solvent. In addition, methods of using said formulations including methods for controlling biological fluid at a desired site in a subject, methods for controlling blood loss, and methods for facilitating effective closure of a vascular wound or incision site at a desired site in a subject are disclosed, the methods comprising administering particular formulations comprising liquid-crystal forming compounds and solvents that are described herein.
Abstract: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.
Type:
Grant
Filed:
October 6, 2009
Date of Patent:
August 27, 2013
Assignee:
Foamix Ltd.
Inventors:
Dov Tamarkin, David Schuz, Yohan Hazot, Elana Gazal
Abstract: A personal care composition in the form of an aqueous gel may comprise an alpha-hydroxy acid, wherein the pH of the composition is less than about 4.5. The personal care composition comprises a gelling agent and an aqueous solvent. The personal care composition further comprises particulates and an effective amount of suspension agent to suspend the particulates. The personal care composition exhibits a consumer desired viscosity and translucency.
Type:
Grant
Filed:
October 28, 2009
Date of Patent:
April 24, 2012
Assignee:
The Procter & Gamble Company
Inventors:
Susan Adair Griffiths-Brophy, Dennis Eugene Kuhlman
Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Type:
Grant
Filed:
July 8, 2008
Date of Patent:
March 20, 2012
Assignee:
MediciNova, Inc.
Inventors:
Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
Abstract: The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) an unbranched or branched alcohol having from 1 to about 4 carbon atoms present in an amount up to about 70 wt. %; and (c) the balance water. The present invention also provides a physiologically compatible conductive agent comprising long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) a surface tension reducing amount of a surfactant; and (c) the balance water.
Abstract: Provided is a method for selective extraction of steroid compounds using entrapped ?-cyclodextrin polymers. Particularly, steroid hormones can be effectively selected from a biological sample by selectively extracting steroid compounds using entrapped ?-cyclodextrin polymers, prepared by adding epichlorohydrin to ?-cyclodextrin to prepare a polymer in a gel state, entrapping the polymer and pulverizing the products without using an additional device required in conventional solid-phase extraction.
Type:
Grant
Filed:
November 29, 2007
Date of Patent:
May 31, 2011
Assignee:
Korea Institute of Science and Technology
Inventors:
Man Ho Choi, Dong Hyun Kim, Bong Chul Chung, Ju-Yeon Moon
Abstract: Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.
Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly fenofibrate, are provided. The compositions comprise a therapeutically effective amount of an active agent and a solubilizer. The solubilizer is selected to effectively solubilize active agent in the composition. The solubilizers employed as part of the invention include: a vitamin E substance; monohydric alcohol esters such as trialkyl citrates, lactones and lower alcohol fatty acid esters; nitrogen-containing solvents; phospholipids; glycerol acetates such as acetin, diacetin and triacetin; glycerol fatty acid esters such as mono-, di- and triglycerides and acetylated mono- and diglycerides; propylene glycol esters; ethylene glycol esters; and combinations thereof. The pharmaceutical dosage forms contain the compositions in a suitable dosage form unit such as a capsule. Methods of treating patients comprising administering the compositions are also provided.
Abstract: This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure:
and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.
Type:
Grant
Filed:
September 25, 2000
Date of Patent:
December 14, 2004
Assignee:
American Cyanamid Company
Inventors:
Joseph K. Yoon, Richard W Saunders, Mahdi Fawzi
Abstract: The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.
Abstract: Physiologically acceptable aqueous solutions and methods for their use are provided. The subject solutions comprise: electrolytes; a dynamic buffering system and an oncotic agent; and do not comprise a conventional biological buffer. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.
Type:
Grant
Filed:
April 20, 2000
Date of Patent:
January 20, 2004
Assignee:
BioTime, Inc.
Inventors:
Paul E. Segall, Hal Sternberg, Harold D. Waitz, Judith M. Segall
Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.
Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.
Type:
Grant
Filed:
August 15, 2001
Date of Patent:
July 29, 2003
Assignees:
Northeastern Ohio Universities College of Medicine, Kent State University
Abstract: The present invention demonstrates a method for inhibiting O-linked protein glycosylation in a tissue or cell, comprising the step of contacting said tissue or cell with (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate or a derivative thereof. The present invention is also directed to a method of treating or inhibiting the onset of diabetes mellitis in an individual in need of such treatment, comprising the step of admininstering to said individual a pharmacological dose of a compound which inhibiting O-linked protein glycosylation in a tissue or cell of said individual. Further, the present invention provides a pharmaceutical composition, comprising (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate and a pharmaceutically acceptable carrier or a derivative thereof.
Abstract: Use of compounds modulating P2 purinoceptors, in particular antagonists such as Basilen Blue E-3G (Reactive Blue 2), for the prevention of the damages due to global cerebral ischemia and ischemia-reperfusion. Said compounds reduce the mortality in case of global cerebral ischemia as well as the neuronal damage of the hippocampus.
Type:
Grant
Filed:
September 19, 2001
Date of Patent:
May 6, 2003
Assignees:
Consiglio Nazionale delle Ricerche, Fondazione Santa Lucia
Inventors:
Cinzia Volonteā², Giuseppe Sancesario, Giorgio Bernardi